Anticancer therapy with checkpoint inhibitors: what, where and when?

This publication has 56 references indexed in Scilit:

• RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
  Proceedings of the National Academy of Sciences, 2011
• Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells
  Molecular Pharmacology, 2010
• Probing the Probes: Fitness Factors For Small Molecule Tools
  Chemistry & Biology, 2010
• Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors
  British Journal of Pharmacology, 2010
• Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
  The Journal of Pharmacology and Experimental Therapeutics, 2009
• Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
  DNA Repair, 2009
• Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival
  Molecular Pharmacology, 2009
• Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
  Current Opinion in Cell Biology, 2009
• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
  British Journal of Cancer, 2008
• Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1)
  Proceedings of the National Academy of Sciences, 2006